Study of 68Ga-R10602

NCT06745804 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
Metastatic Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Adenocarcinoma

Interventions

DRUG: 68Ga-R10602 injection

Sponsor

Radionetics Oncology